Ikarian Capital
Latest statistics and disclosures from Ikarian Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SPY, XLRN, TLT, REGN, BIIB, and represent 41.61% of Ikarian Capital's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$309.30M), XLRN (+$68.87M), TLT (+$65.99M), REGN (+$63.48M), BIIB (+$45.71M), ALNY (+$39.97M), ARGX (+$35.13M), ZGNX (+$33.61M), QQQ (+$29.55M), AXSM (+$29.24M).
- Started 48 new stock positions in Artara Therapeutics Inc, FATE, RLMD, MYOV, TLT, CBAY, NTLA, SAVA, KDMN, BMY.R.
- Reduced shares in these 10 stocks: ICPT (-$37.63M), IBB (-$30.13M), , GILD (-$18.69M), ITCI (-$14.48M), BGNE (-$12.76M), APLS (-$12.72M), GOSS (-$12.05M), GWPH (-$10.46M), KALA (-$8.13M).
- Sold out of its positions in AGIO, AIMT, ALPN, ANAB, APTO, ArQule, BGNE, DCPH, EIDX, GWPH. GOSS, INCY, IBB, MGTA, MTEM, NVAX, PIRS, DTIL, Proteon Therapeutics, Sierra Oncology, TGTX, XFOR, PRTA, WVE.
- Ikarian Capital was a net buyer of stock by $849.95M.
- Ikarian Capital has $1.33B in assets under management (AUM), growing by 115.46%.
Portfolio Holdings for Ikarian Capital
Companies in the Ikarian Capital portfolio as of the March 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Share Count | Change in Shares | Price |
|---|---|---|---|---|
| SPDR S&P 500 ETF (SPY) | 23.26 | 1.20M | NEW | 257.75 |
| Acceleron Pharma (XLRN) | 5.18 | 766.35k | NEW | 89.87 |
| iShares Barclays 20+ Yr Treas.Bond (TLT) | 4.96 | 400.00k | NEW | 164.97 |
| Regeneron Pharmaceuticals (REGN) | 4.77 | 130.00k | NEW | 488.29 |
| Biogen Idec (BIIB) | 3.44 | 144.19k | NEW | 316.98 |
| Alnylam Pharmaceuticals (ALNY) | 3.01 | 367.20k | NEW | 108.85 |
| SPDR S&P Biotech (XBI) | 2.91 | 500.00k | +42% | 77.44 |
| Zogenix (ZGNX) | 2.81 | 1.51M | +889% | 24.73 |
| Argenx Se (ARGX) | 2.64 | 266.66k | NEW | 131.73 |
| Axsome Therapeutics (AXSM) | 2.32 | 525.00k | +1781% | 58.83 |
| Invesco Qqq Trust Series 1 (QQQ) | 2.22 | 550.00k | NEW | 53.73 |
| Myokardia (MYOK) | 1.88 | 533.00k | +803% | 46.88 |
| iShares Russell 2000 Index (IWM) | 1.42 | 165.15k | NEW | 114.49 |
| Gilead Sciences (GILD) | 1.41 | 250.00k | -50% | 74.76 |
| Reata Pharmaceuticals Inc Cl A (RETA) | 1.36 | 125.00k | NEW | 144.34 |
| Alexion Pharmaceuticals (ALXN) | 1.35 | 200.00k | NEW | 89.79 |
| Bioxcel Therapeutics (BTAI) | 1.34 | 797.02k | +403% | 22.35 |
| ACADIA Pharmaceuticals (ACAD) | 1.24 | 390.00k | +178% | 42.25 |
| Ligand Pharmaceuticals In (LGND) | 1.09 | 200.00k | NEW | 72.72 |
| Intercept Pharmaceuticals In (ICPT) | 1.05 | 222.10k | -72% | 62.96 |
| Verastem (VSTM) | 1.04 | 5.25M | NEW | 2.64 |
| Immunovant (IMVT) | 0.99 | 842.46k | +67% | 15.57 |
| Biohaven Pharmaceutical Holding (BHVN) | 0.90 | 350.00k | +74% | 34.03 |
| Mirati Therapeutics (MRTX) | 0.86 | 148.90k | 76.87 | |
| Abbvie (ABBV) | 0.86 | 150.00k | NEW | 76.19 |
| Karyopharm Therapeutics (KPTI) | 0.85 | 588.22k | +193% | 19.21 |
| Cytokinetics (CYTK) | 0.78 | 884.40k | NEW | 11.79 |
| Artara Therapeutics | 0.78 | 450.77k | NEW | 23.00 |
| Adverum Biotechnologies (ADVM) | 0.77 | 224.40k | -42% | 45.48 |
| Sarepta Therapeutics (SRPT) | 0.75 | 102.60k | 97.82 | |
| Aduro Biotech (ADRO) | 0.75 | 3.64M | +97% | 2.74 |
| Fibrogen (FGEN) | 0.73 | 280.00k | NEW | 34.75 |
| Sage Therapeutics (SAGE) | 0.73 | 337.35k | +153% | 28.72 |
| Neurocrine Biosciences (NBIX) | 0.65 | 100.00k | +1288% | 86.55 |
| Ardelyx (ARDX) | 0.63 | 1.46M | +126% | 5.69 |
| Scpharmaceuticals (SCPH) | 0.60 | 1.07M | NEW | 7.40 |
| Ocular Therapeutix (OCUL) | 0.58 | 1.56M | +120% | 4.95 |
| Crispr Therapeutics (CRSP) | 0.57 | 179.10k | +44% | 42.41 |
| Insmed (INSM) | 0.57 | 472.92k | +672% | 16.03 |
| Chiasma (CHMA) | 0.57 | 2.08M | +88% | 3.65 |
| Kura Oncology (KURA) | 0.57 | 759.80k | NEW | 9.95 |
| Cara Therapeutics (CARA) | 0.57 | 571.76k | +2510% | 13.21 |
| Clovis Oncology (CLVS) | 0.57 | 1.19M | +131% | 6.36 |
| Millendo Therapeutics (MLND) | 0.56 | 1.40M | NEW | 5.28 |
| Kalvista Pharmaceuticals (KALV) | 0.54 | 946.61k | +345% | 7.65 |
| Galapagos Nv-spon (GLPG) | 0.52 | 35.00k | NEW | 195.91 |
| Blueprint Medicines (BPMC) | 0.51 | 116.00k | NEW | 58.48 |
| Flamel Technologies Sa (AVDL) | 0.50 | 832.14k | NEW | 7.94 |
| Strongbridge Bioph shs usd (SBBP) | 0.48 | 3.39M | NEW | 1.89 |
| Chemocentryx (CCXI) | 0.45 | 150.00k | +223% | 40.18 |
| Cel Sci (CVM) | 0.43 | 500.00k | +66% | 11.54 |
| Kiniksa Pharmaceuticals (KNSA) | 0.42 | 358.92k | NEW | 15.48 |
| Kadmon Hldgs (KDMN) | 0.41 | 1.32M | NEW | 4.19 |
| Ultragenyx Pharmaceutical (RARE) | 0.38 | 114.25k | +128% | 44.43 |
| Xenon Pharmaceuticals (XENE) | 0.38 | 443.58k | +82% | 11.34 |
| Aurinia Pharmaceuticals (AUPH) | 0.35 | 318.77k | -33% | 14.51 |
| Global Blood Therapeutics In (GBT) | 0.35 | 90.00k | -10% | 51.09 |
| Assembly Biosciences (ASMB) | 0.34 | 307.47k | 14.83 | |
| Minerva Neurosciences (NERV) | 0.33 | 723.80k | +314% | 6.02 |
| Kala Pharmaceuticals (KALA) | 0.33 | 493.95k | -65% | 8.79 |
| Tricida (TCDA) | 0.30 | 179.80k | NEW | 22.00 |
| Intra Cellular Therapies (ITCI) | 0.29 | 249.00k | -79% | 15.37 |
| Ascendis Pharma A S (ASND) | 0.28 | 70.00k | 53.73 | |
| Rts/bristol-myers Squibb Compa (BMY.R) | 0.27 | 950.00k | NEW | 3.80 |
| Bluebird Bio (BLUE) | 0.26 | 76.50k | NEW | 45.96 |
| Cymabay Therapeutics (CBAY) | 0.26 | 2.37M | NEW | 1.48 |
| Myovant Sciences (MYOV) | 0.26 | 450.00k | NEW | 7.55 |
| Otonomy (OTIC) | 0.25 | 1.67M | +56% | 1.97 |
| Madrigal Pharmaceuticals (MDGL) | 0.20 | 40.33k | -72% | 66.77 |
| Allakos (ALLK) | 0.20 | 60.00k | -62% | 44.50 |
| Rigel Pharmaceuticals (RIGL) | 0.20 | 1.68M | +380% | 1.56 |
| Bridgebio Pharma (BBIO) | 0.19 | 87.90k | NEW | 29.00 |
| Solid Biosciences (SLDB) | 0.18 | 988.85k | +223% | 2.39 |
| Intellia Therapeutics (NTLA) | 0.17 | 184.99k | NEW | 12.23 |
| Arvinas Ord (ARVN) | 0.17 | 56.10k | +804% | 40.30 |
| Fate Therapeutics (FATE) | 0.17 | 100.20k | NEW | 22.22 |
| Casi Pharmaceuticalsinc Com Stk (CASI) | 0.16 | 1.04M | NEW | 2.04 |
| Macrogenics (MGNX) | 0.16 | 360.03k | +124% | 5.82 |
| Relmada Therapeutics (RLMD) | 0.14 | 55.17k | NEW | 34.11 |
| Inovio Pharmaceuticals (INO) | 0.14 | 250.00k | NEW | 7.44 |
| Adma Biologics (ADMA) | 0.14 | 630.00k | NEW | 2.88 |
| Applied Genetic Technol Corp C (AGTC) | 0.13 | 545.88k | +171% | 3.28 |
| Albireo Pharma (ALBO) | 0.12 | 100.50k | NEW | 16.37 |
| Immunomedics (IMMU) | 0.12 | 116.10k | -74% | 13.48 |
| Nextcure (NXTC) | 0.11 | 40.70k | NEW | 37.08 |
| Cerecor (CERC) | 0.11 | 564.00k | +8% | 2.48 |
| Apellis Pharmaceuticals (APLS) | 0.10 | 52.13k | -90% | 26.78 |
| Coherus Biosciences (CHRS) | 0.10 | 84.10k | 16.22 | |
| Aptinyx (APTX) | 0.10 | 591.00k | NEW | 2.16 |
| Cassava Sciences (SAVA) | 0.09 | 300.00k | NEW | 4.11 |
| Cortexyme (CRTX) | 0.09 | 25.00k | NEW | 45.60 |
| Ovid Therapeutics (OVID) | 0.08 | 377.74k | +7% | 2.98 |
| Protagonist Therapeutics (PTGX) | 0.08 | 158.22k | +102% | 7.06 |
| Dbv Technologies S A (DBVT) | 0.08 | 280.91k | +276% | 3.92 |
| Inflarx Nv (IFRX) | 0.08 | 262.60k | -26% | 3.82 |
| Mustang Bio (MBIO) | 0.07 | 356.48k | +10% | 2.68 |
| Bellus Health (BLU) | 0.07 | 63.72k | 13.98 | |
| Icad (ICAD) | 0.06 | 107.10k | NEW | 7.34 |
| Viking Therapeutics (VKTX) | 0.04 | 126.16k | -70% | 4.68 |
| Pfenex (PFNX) | 0.04 | 64.21k | NEW | 8.81 |
| Kodiak Sciences (KOD) | 0.04 | 11.80k | NEW | 47.71 |
| Progenics Pharmaceuticals (PGNX) | 0.04 | 130.84k | 3.80 | |
| Puma Biotechnology (PBYI) | 0.03 | 54.90k | -87% | 8.43 |
| Axovant Gene The (AXGT) | 0.03 | 188.88k | 2.44 | |
| Baudax Bio (BXRX) | 0.03 | 175.00k | NEW | 2.48 |
| Mallinckrodt Pub (MNK) | 0.03 | 194.32k | -62% | 1.98 |
| Chimerix (CMRX) | 0.02 | 208.26k | +20% | 1.44 |
| Cellectis S A (CLLS) | 0.02 | 30.93k | NEW | 9.21 |
| Dicerna Pharmaceuticals (DRNA) | 0.02 | 15.50k | 18.39 | |
| Arrowhead Pharmaceuticals (ARWR) | 0.02 | 7.20k | -96% | 28.75 |
| Obseva Sa (OBSV) | 0.01 | 82.57k | 2.41 | |
| Amarin Corporation (AMRN) | 0.01 | 39.70k | -81% | 4.00 |
| Aeterna Zentaris (AEZS) | 0.00 | 117.44k | 0.51 | |
| Stealth Biotherapeutics Corp (MITO) | 0.00 | 37.60k | 1.25 | |
| Sunesis Pharmaceuticals Inc Ne (SNSS) | 0.00 | 111.44k | 0.41 |
Download CSV 
Past Filings by Ikarian Capital
View past SEC 13F filings by Ikarian Capital
- Ikarian Capital 2019 Q4 filed Jan. 31, 2020